Actively Recruiting
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Led by Institut Paoli-Calmettes · Updated on 2026-03-13
35
Participants Needed
1
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE. The main question it aims to answer is to assess the tumor response after 2 cycles of DASATINIB monotherapy treatment for patients with chemotherapy-ineligible acute myeloid leukemia refractory to VENETOCLAX-AZACITIDINE therapy. Participants will be given DASATINIB treatment up to 3 months. Response will be assessed by a myelogram and a complete blood count at the end of every cycle. Follow up will last 6 months.
CONDITIONS
Official Title
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of AML except Philadelphia chromosome-positive AML and acute promyelocytic leukemia
- Age 18 years or older
- ECOG performance status of 3 or less
- No response after two cycles of VENETOCLAX-AZACITIDINE treatment
- Signed informed consent form
- Affiliated with or beneficiary of a social security system
You will not qualify if you...
- Eligible for a targeted therapy with market authorization
- Central nervous system involvement
- Heart failure
- Liver failure
- Kidney failure
- Contraindication to DASATINIB
- Positive for HIV, Hepatitis B, or Hepatitis C
- Pregnant or breastfeeding
- No effective contraception for women of childbearing age
- Emergency situation or unable to give informed consent
- Under legal protection measures
- Unable to follow trial medical requirements due to geographic, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Paoli Calmettes
Marseille, France
Actively Recruiting
Research Team
J
Jihane PAKARANOUNI, PharmD,PhD
CONTACT
L
Laurie-Anne GOUTY, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here